Companies in the biotech and pharmaceutical industries are subject to a sizable amount of risk with regards to their drug candidates passing clinical trials and gaining regulatory approval. But with the risk of failure, which could spell disaster for a stock, comes great reward as well. Some companies can see a massive upside just from winning a single midstage trial or even achieving as much as a Fast Track designation from the U.S. Food and Drug Administration (FDA).
Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week and the rest of June.
Global Blood Therapeutics Inc. (NASDAQ: GBT) is making a presentation at the SCD Research and Educational Symposium on June 15 to 17. Shares of GBT were last seen at $48.05 on Friday, with a consensus analyst price target of $72.46 and a 52-week trading range of $24.02 to $68.05.
Argenx S.E. (NASDAQ: ARGX) is making a presentation at the Immune Thrombocytopenia Breakfast Symposium on June 19 for its human monoclonal antibody Efgartigimod (ARGX 113). Argenx shares were trading at $99.95 on Friday, with a consensus price target of $91.01 and a 52-week range of $19.00 to $101.46.
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) is making presentations at the American Diabetes Association on June 22 to 26. Lexicon recently traded at $12.92 a share, with a consensus price target of $23.00 and a 52-week range of $7.67 to $18.00.
Achaogen Inc. (NASDAQ: AKAO) has a Prescription Drug User Fee Act (PDUFA) date scheduled for June 25 for its lead product plazomicin, which is being developed to treat serious bacterial infections. Achaogen shares traded at $11.98, with a consensus price target of $18.20 and a 52-week range of $9.83 to $25.22.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is readying for its commercial launch of Palynziq (pegvaliase) in the United States, for the treatment of phenylketonuria. Shares of BioMarin were trading at $90.56, with a consensus analyst target of $111.14 and a 52-week range of $75.81 to $100.03.